Celgene BCMA ASH Booth
- Indication Oncology
- Celgene / Bristol Myers Squibb
This experience at ASH 2019 highlighted three different types of agents that target the BCMA protein present on plasma cells to treat multiple myeloma.
It consisted of a large LED video panel, where users could press one of three illuminated buttons on a central kiosk to initiate a MOA video chapter about one of the three classes of BCMA-targeted treatments in the pipeline — CAR-T, T-Cell Engager (TCE), and Antibody-Drug Conjugate (ADC).
Attendees could then visit two supporting digital panels to take a deeper dive into the classes themselves, or view clinical trial cards about specific compounds under investigation.